The stock of Geron Corp. (NASDAQ:GERN) last traded at $1.99, up 1.53% from the previous session.
Data from the available sources indicates that Geron Corp. (NASDAQ:GERN) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.00, we find $5.00. Given the previous closing price of $1.96, this indicates a potential upside of 155.1 percent. GERN stock price is now 5.22% away from the 50-day moving average and -21.67% away from the 200-day moving average. The market capitalization of the company currently stands at $1.08B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 0 analysts have assigned it a hold rating, and 5 have given it a buy rating. Brokers who have rated the stock have averaged $4.83 as their price target over the next twelve months.
With the price target maintained at $4, Goldman recently Upgraded its rating from Neutral to Buy for Geron Corp. (NASDAQ: GERN).
In other news, O’Farrell Elizabeth G., Director bought 6,607 shares of the company’s stock on Aug 24. The stock was bought for $15,064 at an average price of $2.28. Upon completion of the transaction, the Director now directly owns 7,407 shares in the company, valued at $14739.93. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 24, Director O’Farrell Elizabeth G. bought 6,579 shares of the business’s stock. A total of $15,000 was incurred on buying the stock at an average price of $2.28. This leaves the insider owning 26,220 shares of the company worth $52177.8. Insiders disposed of 2,194,719 shares of company stock worth roughly $4.37 million over the past 1 year. A total of 16.00% of the company’s stock is owned by insiders.
With an opening price of $1.9800 on Wednesday morning, Geron Corp. (NASDAQ: GERN) set off the trading day. During the past 12 months, Geron Corp. has had a low of $1.68 and a high of $3.84. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 3.75, and a quick ratio of 3.75. The fifty day moving average price for GERN is $1.8912 and a two-hundred day moving average price translates $2.5405 for the stock.
The latest earnings results from Geron Corp. (NASDAQ: GERN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.08, beating analysts’ expectations of -$0.1 by 0.02. This compares to -$0.10 EPS in the same period last year. The net profit margin was -55138.49% and return on equity was -87.66% for GERN. The company reported revenue of $0.16 million for the quarter, compared to $0.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -44.78 percent. For the current quarter, analysts expect GERN to generate $70k in revenue.
Geron Corp.(GERN) Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
